Biotech startup lines up more cash to steer its NASH drug through stormy seas

In January 2020, Dutch NASH-focused biotech NorthSea Therapeutics raised $40 million in a Series B to progress its lead candidate icosabutate, a structurally-engineered fatty compound for NASH. Just shy of two years later, NorthSea has completed another round of financing, netting a $80 million Series C to start a Phase III in NASH and advance several other candidates.